Study of XL820 in Adults With Solid Tumors

Completed · Phase 1

Conditions studied: Cancer

In brief

The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.

Key facts

Study ID

NCT00129571

Run by

Exelixis

Starts

2005-08-01

Last updated by the study team

2008-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced solid tumor
• Cancer for which standard therapies do not exist or are no longer effective
• Life expectancy of > 3 months
• Adequate bone marrow, liver, and kidney function
• Willing to use accepted method of contraception during the course of the study
• Negative pregnancy test (females)
• Written informed consent

You may not qualify if…

• Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
• Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment
• Investigational drug within 30 days of the start of treatment
• Subjects with known brain metastasis
• Uncontrolled medical disorder such as infection or cardiovascular disease
• Subjects known to be HIV positive
• Pregnant or breastfeeding women

Where it is running

• The Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
• Cancer Therapy and Research Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.